Can dexmedetomidine be a safe and efficacious sedative agent in post-cardiac surgery patients? a meta-analysis

• Published in: Critical care (London, England) England), 2012-09, Vol.16 (5), p.R169-R169, Article R169
• Main Authors: Lin, Yi Yun, He, Bin, Chen, Jian, Wang, Zhi Nong
• Format: Article
• Language: English
• Subjects: Analysis; Atrial fibrillation; Cardiac patients; Cardiac Surgical Procedures - adverse effects; Cardiac Surgical Procedures - trends; Cohort Studies; Coronary artery bypass; Dexmedetomidine; Dexmedetomidine - administration & dosage; Dexmedetomidine - adverse effects; Drug therapy; Health aspects; Hospital patients; Humans; Hyperglycemia; Hypnotics and Sedatives - administration & dosage; Hypnotics and Sedatives - adverse effects; Nausea; Postoperative Care - methods; Postoperative Care - trends; Randomized Controlled Trials as Topic - trends; Respiration, Artificial - trends; Tachycardia; Treatment Outcome
• ISSN: 1364-8535; 1466-609X; 1364-8535
• DOI: 10.1186/cc11646

The aim of this study was to explore the use of dexmedetomidine as a safe and efficacious sedative agent in post-cardiac surgery patients. A systematic literature search of MEDLINE, EMBASE, the Cochrane Library and Science Citation Index until January 2012 and review of studies was conducted. Eligible studies were of randomized controlled trials or cohort studies, comparing dexmedetomidine with a placebo or an alternative sedative agent in elective cardiac surgery, using dexmedetomidine for postoperative sedation and available in full text. Two reviewers independently performed study selection, quality assessment, and data extraction. The search identified 530 potentially relevant publications; 11 met selection criteria in this meta-analysis. Our results revealed that dexmedetomidine was associated with a shorter length of mechanical ventilation (mean difference -2.70 [-5.05, -0.35]), a lower risk of delirium (risk ratio 0.36 [0.21, 0.64]), ventricular tachycardia (risk ratio 0.27 [0.08, 0.97]) and hyperglycemia (risk ratio 0.78 [0.61, 0.99]), but may increase the risk of bradycardia (risk ratio 2.08 [1.16, 3.74]). But there was no significant difference in ICU stay, hospital stay, and morphine equivalents between the included studies. Dexmedetomidine may not increase the risk of hypotension, atrial fibrillation, postoperative nausea and vomiting, reintubation within 5 days, cardiovascular complications, postoperative infection or hospital mortality. Dexmedetomidine was associated with shorter length of mechanical ventilation and lower risk of delirium following cardiac surgery. Although the risk of bradycardia was significantly higher compared with traditional sedatives, it may not increase length of hospital stay and hospital mortality. Moreover, dexmedetomidine may decrease the risk of ventricular tachycardia and hyperglycemia. Thus, dexmedetomidine could be a safe and efficacious sedative agent in cardiac surgical patients.